Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wunsch, Ewa ^a   Milkiewicz, Malgorzata ^a   Wasik, Urszula ^a   Trottier, Jocelyn ^b   Kempialska Podhorodecka, Agnieszka ^a   Elias, Elwyn ^c   Barbier, Olivier ^b   Milkiewicz, Piotr ^a,d  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; FGF19 PROTEIN, HUMAN; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MESSENGER RNA;

BILIARY CIRRHOSIS; BLOOD; CASE CONTROL STUDY; FEMALE; GENETICS; HUMAN; LIVER; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

BILE ACIDS AND SALTS; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; PHOSPHORYLATION; QUALITY OF LIFE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX;

EID: 84940040449     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13462     Document Type: Article

References (41)

1. Kaplan, M. M. & Gershwin, M. E. Primary biliary cirrhosis. N Engl J Med. 22, 1261-1273. (2005)
2. Milkiewicz, P. & Heathcote, E. J. Fatigue in chronic cholestasis. Gut. 53, 475-477 (2004)
3. Newton, J. L. et al. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology. 48, 541-549 (2008)
4. Gershwin, M. E., Mackay, I. R., Sturgess, A. & Coppel, R. L. Identifcation and specifcity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol. 15, 3525-3531 (1987)
5. Pauli-Magnus, C., Stieger, B., Meier, Y., Kullak-Ublick, G. A. & Meier, P. J. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol. 43, 342-357 (2005)
6. Trauner, M., Wagner, M., Fickert, P. & Zollner, G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol. 39(4 Suppl 2), 111-124 (2005)
7. Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217-225 (2005)
8. Holt, J. A. et al. Defnition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 1, 1581-1591 (2003)
9. Zollner, G. et al. Coordinated induction of bile acid detoxifcation and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol. 290, G923-G932. (2006)
10. Choi, M. et al. Identifcation of a hormonal basis for gallbladder flling. Nat Med. 12, 1253-1255 (2006)
11. Fu, L. et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-defcient diabetes. Endocrinology. 145, 2594-2603 (2004)
12. Wu, A. L. et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One. 6, e17868 (2011)
13. Beenken, A. & Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8, 235-253 (2009)
14. Zhang, J. H. et al. Potent stimulation of fbroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol. 304, G940-G948 (2013)
15. Jonker, J. W., Liddle, C. & Downes, M. FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol. 130, 147-158 (2012)
16. Li, T., Jahan, A. & Chiang, J. Y. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology 43, 1202-1210 (2006)
17. Miao, J. et al. Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. Genes Dev. 15, 986-996 (2009)
18. Kong, B. et al. Mechanism of tissue-specifc farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 56, 1034-1043 (2012)
19. Schaap, F. G., van der Gaag, N. A., Gouma, D. J. & Jansen, P. L. High expression of the bile salt-homeostatic hormone fbroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49, 1228-1235 (2009)
20. Song, K. H., Li, T., Owsley, E., Strom, S. & Chiang, J. Y. Bile acids activate fbroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49, 297-305 (2009)
21. Nishimura, T., Utsunomiya, Y., Hoshikawa, M., Ohuchi, H. & Itoh, N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta. 18, 148-151 (1999)
22. Modica, S. et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology. 142, 355-365 (2012)
23. Kong, B. et al. Fibroblast growth factor 15 defciency impairs liver regeneration in mice. Am J Physiol Gastrointest Liver Physiol. 15, G893-G902 (2014)
24. Uriarte, I. et al. Identifcation of fbroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut. 62, 899-910 (2013)
25. Miura, S. et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 12: 56. (2012)
26. Nicholes, K. et al. A mouse model of hepatocellular carcinoma: ectopic expression of fbroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol. 160, 2295-2307 (2002)
27. Zhou, M. et al. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. Cancer Res. 15, 3306-3316 (2014)
28. Schaap, F. G., Trauner, M. & Jansen, P. L. Bile acid receptors as targets for drug development. Nat. Rev. Gastroenterol Hepatol. 11, 55-67 (2014).
29. Hirschfeld, G. M. et al. Efcacy of obeticholic Acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic Acid. Gastroenterology 148, 751-761 (2015).
30. Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965 (2015).
31. Wunsch, E. et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology. 60, 931-940 (2014)
32. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 51, 237-267 (2009)
33. Kopycinska, J. et al. Activation of FoxO3a/Bim axis in patients with Primary Biliary Cirrhosis. Liver Int. 33, 231-238 (2013)
34. Milkiewicz, M. et al. Ursodeoxycholic acid infuences the expression of p27kip1 but not FoxO1 in patients with non-cirrhotic primary biliary cirrhosis. J Immunol Res. 921285. doi: 10.1155/2014/921285 (2014)
35. Trottier, J. et al. Profling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofbrate. Clin Pharmacol Ter. 94, 533-543 (2013)
36. Trottier, J. et al. Profling circulating and urinary bile acids in patients with biliary obstruction before and afer biliary stenting. PLoS One 6, e22094 (2011)
37. Trottier, J., Caron, P., Straka, R. J. & Barbier, O. Profile of serum bile acids in noncholestatic volunteers: gender-related diferences in response to fenofbrate. Clin Pharmacol Ter 90, 279-286 (2011)
38. Trottier, J. et al. Metabolomic profling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis 44, 303-310 (2012)
39. Jacoby, A. et al. Development, validation, and evaluation of the PBC-40, a disease specifc health related quality of life measure for primary biliary cirrhosis. Gut. 54, 1622-1629 (2005)
40. Montali, L. et al. A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis. Dig Liver Dis. 42, 718-723 (2010)
41. Ware, J. E., Jr. & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 30, 473-483 (1992)